14:19 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

MAT2A identified as a target in solid and liquid cancers

DISEASE CATEGORY: Cancer INDICATION: Lung; leukemia; lymphoma; solid tumors Cell and mouse studies suggest inhibiting MAT2A could help treat lung and other solid and liquid cancers. In a panel of human cancer cell lines, including...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
23:54 , Apr 26, 2018 |  BC Innovations  |  Targets & Mechanisms

Raising metabolism

In the wake of the failure of ECHO-301, drug developers are asking whether the trial design or the target is at fault. But while the value of IDO1 as a target is still in doubt,...
17:09 , Sep 29, 2017 |  BioCentury  |  Strategy

Agios’ acceleration

A biomarker-driven strategy in a setting where response was easy to measure, along with a healthy pile of cash, allowed Agios Pharmaceuticals Inc. to go from concept to marketed drug in just over eight years....